OPRXNasdaqServices-Business Services, NECFiscal year ends December 31
OptimizeRx Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.74+0.24 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $164.19M
- P/E (TTM)
- 36.4
- Dividend yield
- –
Share price
−$10.81 (−55.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
OptimizeRx Corp saw revenue fall 5.8% to $98.65M over the twelve months to Jun 30, 2026. Free cash flow was $18.36M, up 77.5% from a year earlier.
Revenue
$98.65M
-5.8% vs. a year earlier
Operating income
$10.93M
TTM Q2 2026
Free cash flow
$18.36M
+77.5% vs. a year earlier
EPS, diluted
$0.24
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $164.19M
- P/E ratio
- 36.4
- Price to sales
- 1.66
- Price to book
- 1.25
- Dividend yield
- –
- Free cash flow yield
- 11.18%
Fundamentals
- Revenue
- $98.65M
- Net income
- $4.60M
- EPS, diluted
- $0.24
- Free cash flow
- $18.36M
- Book value per share
- $6.98
- Diluted shares
- 19M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$98.65M-5.8% YoY
Gross profit
$72.24M+7.1% YoY
Operating income
$10.93M
Net income
$4.60M
EPS, diluted
$0.24
Free cash flow
$18.36M+77.5% YoY
Reported periodTrailing twelve months